EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardenolide‐Engineered Extracellular Vesicles Augment Drug Uptake and Cytotoxicity in Non‐small Cell Lung Cancer Cells

Maja Dorfner iD, Anika Mifka, Rodrigo Maia de Pádua iD, Izabella Thaís da Silva iD, Iara Zanella Guterres iD, Lorenzo Sana, Gregor Fuhrmann iD, Jennifer Munkert iD

Small Methods · 2026

DOI: 10.1002/smtd.202501505 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small Methods, 2026. Verfasst von Maja Dorfner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Biology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cardenolides, Extracellular Vesicles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Council for financial support of the PharmBio EV facility for our large-scale equipment, Deutsche Forschungsgemeinschaft, Universitätsbund Erlangen-Nürnberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains a leading cause of premature mortality worldwide. Targeted drug delivery therapies that selectively attack malignant cells while sparing healthy tissue are essential to minimize side effects and reduce drug dosages. The sodium‐potassium ATPase (Na + /K + ‐ATPase), particularly its catalytic α‐subunit, is overexpressed in A549 non‐small cell lung cancer (NSCLC) and has thus emerged as a potential therapeutic target. Cardiac glycosides (CGs), plant‐derived secondary metabolites, specifically bind and inhibit this enzyme providing target engagement. Coupling CGs to a biocompatible carrier provides a promising new approach for a targeted‐orientated drug carrier. Among these nanocarrier systems, cell‐derived extracellular vesicles (EVs) gained attention due to their biocompatibility, tumor‐targeting capability, and ability to encapsulate compounds. Here, we developed a target‐oriented nanocarrier system by linking 3β‐azido‐3‐deoxydigitoxigenin (CA), a semi‐synthetic cardenolide derivative, to the surface of A549 cell‐derived EVs. The EVs were characterized for particle concentration, size and protein markers. Surface modification was achieved via alkyne modification and click chemistry. Successful conjugation was confirmed by inhibition of the Na + /K + ‐ATPase activity. Co‐localization of CA‐modified EVs with the Na + /K + ‐ATPase was verified by confocal microscopy. Doxorubicin‐loaded, CA‐modified EVs reduced A549 cell viability to 45% after 48 h, demonstrating its potential use as new drug nanocarrier system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCardenolidesExtracellular VesiclesDoxorubicinHumansA549 CellsSodium-Potassium-Exchanging ATPaseDrug CarriersCell SurvivalAntineoplastic AgentsDrug Delivery Systems

Stichwörter der Autor:innen

A549 non‐small cell lung cancer (NSCLC) cell lineNa+/K+‐ATPase inhibition assaycardenolide derivative 3β‐azido‐3‐deoxydigitoxigeninsurface‐modification by click chemistrytarget drug delivery

Substanzen

CardenolidesDoxorubicinSodium-Potassium-Exchanging ATPaseDrug CarriersAntineoplastic Agents

Autor:innen und Institutionen

  • Pharmaceutical Biology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
  • Department of Pharmaceutical Products, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
  • Department of Pharmaceutical Sciences, Federal University Santa Catarina, Florianopolis, SC, Brazil.
  • FAU NeW, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Maja Dorfner, Rodrigo Maia de Pádua, Izabella Thaís da Silva, Iara Zanella Guterres, Gregor Fuhrmann, Jennifer Munkert

Förderung

  • German Research Council for financial support of the PharmBio EV facility for our large-scale equipment
  • Deutsche Forschungsgemeinschaft
  • Universitätsbund Erlangen-Nürnberg
  • Bayerisches Hochschulzentrum für Lateinamerika
  • H2020 European Research Council
  • FAU Gender and Diversity Fund
  • Dr. Hertha and Helmut Schmauser-Foundation

Zitieren

APA

Dorfner, M., Mifka, A., de Pádua, R. M., da Silva, I. T., Guterres, I. Z., Sana, L., Fuhrmann, G., & Munkert, J. (2026). Cardenolide‐Engineered Extracellular Vesicles Augment Drug Uptake and Cytotoxicity in Non‐small Cell Lung Cancer Cells. Small Methods. https://doi.org/10.1002/smtd.202501505

Vancouver

Dorfner M, Mifka A, de Pádua RM, da Silva IT, Guterres IZ, Sana L, et al. Cardenolide‐Engineered Extracellular Vesicles Augment Drug Uptake and Cytotoxicity in Non‐small Cell Lung Cancer Cells. Small Methods. 2026. doi:10.1002/smtd.202501505

BibTeX
@article{Dorfner2026,
  author = {Dorfner, Maja and Mifka, Anika and de Pádua, Rodrigo Maia and da Silva, Izabella Thaís and Guterres, Iara Zanella and Sana, Lorenzo and Fuhrmann, Gregor and Munkert, Jennifer},
  title = {Cardenolide‐Engineered Extracellular Vesicles Augment Drug Uptake and Cytotoxicity in Non‐small Cell Lung Cancer Cells},
  journal = {Small Methods},
  year = {2026},
  doi = {10.1002/smtd.202501505}
}
Kostenlos starten →